Vanessa Biotech (VB), a Hamden, Conn.-based biomedical company committed to improving patient quality of life by developing innovative solutions for unmet medical needs, proudly supported Rare Disease Day for the fifth consecutive year.
Rare Disease Day is observed internationally each year on the last day of February, because that day is viewed as the rarest day of the year. The aim of the day is to raise awareness regarding the 300 million people worldwide who are battling rare diseases. Rare Disease Day was first launched internationally by EURORDIS and its Council of National Alliances in 2008. National Organization for Rare Disorders (NORD) became the official US sponsor of Rare Disease Day in 2009. A Vanessa Biotech social media campaign kicked off during February 2022 to help shine a light on rare disease worldwide, and to raise awareness for EURORDIS-Rare Diseases and NORD. The campaign included highlights from rarediseaseday.org and an invitation for employees to join the NORD’s Rare Disease Day event on February 28th. VB currently has orphan drug designation through the European Medicine Agencies for Shylicine™ its candidate for treating MVID; Shylicine™ is currently in a Phase 2 clinical trial.
About Vanessa Biotech
Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.
P.O. Box 185755
Hamden, Conn. 06518 USA
+1 203 836 8424